乌鸦传媒

Study is "a big call-out for us to fight for improved air quality," says Nicholas Rohs, MD

"Unfortunately, it's not a home run," says Roy Herbst, MD, PhD

It's "full speed ahead" for EGFR-positive patients, says Roy Herbst

But James Hu, MD, says he is encouraged that a randomized study was done for this rare tumor

Combination increased PFS as first-line treatment but has expected added toxicities

Edwin Choy briefly describes several abstracts that caught his attention

Bradley Monk, MD, details five potential FDA approvals on the horizon

New cohort adds bevacizumab to olaparib /durvalumab combo